Advertisement

Antipsychotics in the Treatment of Bipolar Disorder

  • Jaskaran Singh
  • Guang Chen
  • Carla M. CanusoEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 212)

Abstract

Atypical antipsychotics have an important role in the acute and maintenance treatment of bipolar disorder. While robust evidence supports the efficacy of these agents in the treatment of mania and in the prevention of manic relapse, few atypical antipsychotics have shown efficacy in the treatment or prevention of depressive episodes. These agents pose a lower risk of extrapyramidal side effects compared to typical neuroleptics, but carry a significant liability for weight gain and other metabolic side effects such as hyperglycemia and hyperlipidemia. More comparative effectiveness studies are needed to assess the optimal treatment regimens, including the relative benefits and risks of antipsychotics versus mood stabilizers. The exploration of the molecular mechanisms of antipsychotics has helped to shed further light on the underlying neurobiology of bipolar disorder, since these compounds target systems thought to be key to the pathophysiology of bipolar disorder. In addition to modulating monoaminergic neurotransmission, atypical antipsychotics appear to share properties with mood-stabilizing agents known to alter intracellular signal transduction leading to changes in neuronal activity and gene expression. Atypical antipsychotic drugs have been shown to exhibit neuroprotective properties that are mediated by upregulation of trophic and cellular resilience factors. Building on our understanding of existing therapeutics, especially as it relates to underlying disease pathology, newer “plasticity enhancing” strategies hold promise for future treatments of bipolar disorder.

Keywords

Bipolar disorder Atypical antipsychotics Monoamines Signal transduction Cellular resilience Neuroplasticity 

References

  1. Amrollahi Z, Rezaei F, Salehi B, Modabbernia AH, Maroufi A, Esfandiari GR et al (2011) Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania. J Affect Disord 129(1–3):327–331PubMedGoogle Scholar
  2. APA (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159(4 Suppl):1–50Google Scholar
  3. Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217PubMedGoogle Scholar
  4. Beaulieu JM, Gainetdinov RR, Caron MG (2007) The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 28(4):166–172PubMedGoogle Scholar
  5. Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347PubMedGoogle Scholar
  6. Beckford-Ball J (2006) An overview of the new NICE guidelines on bipolar disorder. Nurs Times 102(34):23–24Google Scholar
  7. Benyamina A, Samalin L (2012) Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract 16(1):2–7PubMedGoogle Scholar
  8. Berk M, Dodd S, Kauer-Sant’anna M, Malhi GS, Bourin M, Kapczinski F et al (2007) Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 434:41–49PubMedGoogle Scholar
  9. Berwaerts J, Lane R, Nuamah IF, Lim P, Remmerie B, Hough DW (2011) Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 129(1–3):252–260PubMedGoogle Scholar
  10. Blier P, Blondeau C (2011) Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 128(Suppl 1):S3–10PubMedGoogle Scholar
  11. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M et al (2005) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66(1):111–121PubMedGoogle Scholar
  12. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M (2010) Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 71(2):130–137PubMedGoogle Scholar
  13. Calabrese JR, Elhaj O, Gajwani P, Gao K (2005a) Clinical highlights in bipolar depression: focus on atypical antipsychotics. J Clin Psychiatry 66(Suppl 5):26–33PubMedGoogle Scholar
  14. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH et al (2005b) A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162(7):1351–1360PubMedGoogle Scholar
  15. Calabrese J, Stet L, Kotari H (2010) Asenapine as adjunctive treatment for bipolar mania: results of a placebo-controlled 12-week study and 40-week extension. Eur Psychiatry (Supplement 1): 1447Google Scholar
  16. Chang KD (2008) The use of atypical antipsychotics in pediatric bipolar disorder. J Clin Psychiatry 69(Suppl 4):4–8PubMedGoogle Scholar
  17. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 72(2):879–882PubMedGoogle Scholar
  18. Chen G, Henter ID, Manji HK (2010) Translational research in bipolar disorder: emerging insights from genetically based models. Mol Psychiatry 15(9):883–895PubMedGoogle Scholar
  19. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S et al (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 378:1306–15PubMedGoogle Scholar
  20. Collo G, Zanetti S, Missale C, Spano P (2008) Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci 28(7):1231–1240PubMedGoogle Scholar
  21. Corya SA, Perlis RH, Keck PE Jr, Lin DY, Case MG, Williamson DJ et al (2006) A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 67(5):798–806PubMedGoogle Scholar
  22. Councill JH, Tucker ES, Haskell GT, Maynard TM, Meechan DW, Hamer RM et al (2006) Limited influence of olanzapine on adult forebrain neural precursors in vitro. Neuroscience 140(1):111–122PubMedGoogle Scholar
  23. Cousins DA, Young AH (2007) The armamentarium of treatments for bipolar disorder: a review of the literature. Int J Neuropsychopharmacol 10(3):411–431PubMedGoogle Scholar
  24. Cousins DA, Butts K, Young AH (2009) The role of dopamine in bipolar disorder. Bipolar Disord 11(8):787–806PubMedGoogle Scholar
  25. Creson TK, Yuan P, Manji HK, Chen G (2009) Evidence for involvement of ERK, PI3K, and RSK in induction of Bcl-2 by valproate. J Mol Neurosci 37(2):123–134PubMedGoogle Scholar
  26. Cruz N, Sanchez-Moreno J, Torres F, Goikolea JM, Valenti M, Vieta E (2009) Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol 13(1):5–14PubMedGoogle Scholar
  27. Deutch AY, Ongur D, Duman RS (1995) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66(2):337–346PubMedGoogle Scholar
  28. Di Benedetto B, Kuhn R, Nothdurfter C, Rein T, Wurst W, Rupprecht R (2011) N-desalkylquetiapine activates ERK1/2 to induce GDNF release in C6 glioma cells: A putative cellular mechanism for quetiapine as antidepressant. Neuropharmacology 62(1):209–16PubMedGoogle Scholar
  29. DiazGranados N, Zarate CA Jr (2008) A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder. Curr Psychiatry Rep 10(6):510–519PubMedGoogle Scholar
  30. Dwivedi Y, Pandey GN (1999) Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. J Pharmacol Exp Ther 291(2):688–704PubMedGoogle Scholar
  31. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L et al (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23(19):7311–7316PubMedGoogle Scholar
  32. Einat H, Yuan P, Manji HK (2005) Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav Brain Res 165(2):172–180PubMedGoogle Scholar
  33. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C et al (2010) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21(8):621–645PubMedGoogle Scholar
  34. Freyberg Z, Ferrando SJ, Javitch JA (2010) Roles of the Akt/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action. Am J Psychiatry 167(4):388–396PubMedGoogle Scholar
  35. Fumagalli F, Molteni R, Bedogni F, Gennarelli M, Perez J, Racagni G et al (2004) Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. Neuroreport 15(13):2109–2112PubMedGoogle Scholar
  36. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR (2008) Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 28(2):203–209PubMedGoogle Scholar
  37. Gentile S (2007) Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 21(5):367–387PubMedGoogle Scholar
  38. Giese AA (2009) Closing the gap between guidelines for bipolar disorder treatment and clinical practice. Am J Psychiatry 166(11):1205–1206PubMedGoogle Scholar
  39. Goodwin FK (2007) Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press, OxfordGoogle Scholar
  40. Goodwin FK, Jamison KR (2007) Manic-depressive illness: bipolar disorders and recurrent depression, 2nd edn. Oxford University Press, OxfordGoogle Scholar
  41. Gould TD, Picchini AM, Einat H, Manji HK (2006) Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr Drug Targets 7(11):1399–1409, Review. PubMed PMID: 17100580PubMedGoogle Scholar
  42. Green W, Patil P, Marsden CA, Bennett GW, Wigmore PM (2006) Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res 1070(1):242–245PubMedGoogle Scholar
  43. Hammonds MD, Shim SS (2009) Effects of 4-week treatment with lithium and olanzapine on levels of brain-derived neurotrophic factor, B-cell CLL/lymphoma 2 and phosphorylated cyclic adenosine monophosphate response element-binding protein in the sub-regions of the hippocampus. Basic Clin Pharmacol Toxicol 105(2):113–119PubMedGoogle Scholar
  44. He J, Xu H, Yang Y, Zhang X, Li XM (2004) Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res 1018(2):186–192PubMedGoogle Scholar
  45. He J, Xu H, Yang Y, Rajakumar D, Li X, Li XM (2006) The effects of chronic administration of quetiapine on the phencyclidine-induced reference memory impairment and decrease of Bcl-XL/Bax ratio in the posterior cingulate cortex in rats. Behav Brain Res 168(2):236–242PubMedGoogle Scholar
  46. Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M et al (2004) Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161(6):1057–1065PubMedGoogle Scholar
  47. Hunsberger J, Austin DR, Henter ID, Chen G (2009) The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin Neurosci 11(3):333–348PubMedGoogle Scholar
  48. Hunsberger JG, Machado-Vieira R, Austin DR, Zarate C, Chuang DM, Chen G et al (2011) Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res 1403:19–27PubMedGoogle Scholar
  49. Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11(2):77–86PubMedGoogle Scholar
  50. Jarskog LF, Gilmore JH, Selinger ES, Lieberman JA (2000) Cortical bcl-2 protein expression and apoptotic regulation in schizophrenia. Biol Psychiatry 48(7):641–650PubMedGoogle Scholar
  51. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH (2004) Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am J Psychiatry 161(1):109–115PubMedGoogle Scholar
  52. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL (2008) N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology 33(10):2303–2312PubMedGoogle Scholar
  53. Jiao S, Li Z (2011) Nonapoptotic function of BAD and BAX in long-term depression of synaptic transmission. Neuron 70(4):758–772PubMedGoogle Scholar
  54. Jonas E (2006) BCL-xL regulates synaptic plasticity. Mol Interv 6(4):208–222PubMedGoogle Scholar
  55. Jonas EA (2009) Molecular participants in mitochondrial cell death channel formation during neuronal ischemia. Exp Neurol 218(2):203–212PubMedGoogle Scholar
  56. Kapur S, Mann JJ (1992) Role of the dopaminergic system in depression. Biol Psychiatry 32(1):1–17PubMedGoogle Scholar
  57. Kato T (2007) Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 61(1):3–19PubMedGoogle Scholar
  58. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K (2003) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160(4):741–748PubMedGoogle Scholar
  59. Keck PE Jr, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM et al (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68(10):1480–1491PubMedGoogle Scholar
  60. Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A (2010) Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 260(2):151–162PubMedGoogle Scholar
  61. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M (2005) Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 187:229–234PubMedGoogle Scholar
  62. Kim I, Xu W, Reed JC (2008) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7(12):1013–1030PubMedGoogle Scholar
  63. Kim HW, Rapoport SI, Rao JS (2010) Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurobiol Dis 37(3):596–603PubMedGoogle Scholar
  64. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J (2008) Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 28(6):601–607PubMedGoogle Scholar
  65. Kusumakar V (2002) Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 63(Suppl 10):23–28PubMedGoogle Scholar
  66. Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294(5548):1945–1948PubMedGoogle Scholar
  67. Levy B, Manove E (2011) Functional outcome in bipolar disorder: the big picture. Depress Res Treat 2012:949248PubMedGoogle Scholar
  68. Li X, Jope RS (2010) Is glycogen synthase kinase-3 a central modulator in mood regulation? Neuropsychopharmacology 35(11):2143–2154PubMedGoogle Scholar
  69. Lien R, Flaisher-Grinberg S, Cleary C, Hejny M, Einat H (2008) Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacol Rep 60(4):490–498PubMedGoogle Scholar
  70. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60(3):358–403, Review. Erratum in: Pharmacol Rev. 2008 Dec;60(4):582. PubMed PMID: 18922967PubMedGoogle Scholar
  71. Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, Liu F et al (2011) Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse 65(3):234–248PubMedGoogle Scholar
  72. Luo C, Xu H, Li XM (2004) Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine. Brain Res 1025(1–2):194–202PubMedGoogle Scholar
  73. Macfadden W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C et al (2009) A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 11(8):827–839PubMedGoogle Scholar
  74. Machado-Vieira R, Pivovarova NB, Stanika RI, Yuan P, Wang Y, Zhou R et al (2011) The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder. Biol Psychiatry 69(4):344–352PubMedGoogle Scholar
  75. Maeng S, Hunsberger JG, Pearson B, Yuan P, Wang Y, Wei Y et al (2008) BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proc Natl Acad Sci U S A 105(25):8766–8771PubMedGoogle Scholar
  76. Malkesman O, Austin DR, Tragon T, Henter ID, Reed JC, Pellecchia M, et al (2011) Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol PsychiatryGoogle Scholar
  77. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W et al (2011) Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 13(2):133–144PubMedGoogle Scholar
  78. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J (2005) Quetiapine or haloperidol as monotherapy for bipolar mania–a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15(5):573–585PubMedGoogle Scholar
  79. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2009) Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 11(8):815–826PubMedGoogle Scholar
  80. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J (2010) Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord 122(1–2):27–38PubMedGoogle Scholar
  81. McQuade R, Marcus R, Sanchez R (2003) Aripiprazole vs placebo in acute mania: safety and tolerability pooled analysis. Paper presented at the 5th International Conference on Bipolar Disorder, Pittsburgh, PAGoogle Scholar
  82. Merlo S, Canonico PL, Sortino MA (2011) Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype. Neuropharmacology 60(6):892–900PubMedGoogle Scholar
  83. Montezinho LP, Castro MM, Duarte CB, Penschuck S, Geraldes CF, Mork A (2006) The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 96(5):1336–1348PubMedGoogle Scholar
  84. Mullen J, Devine N, Sweitzer D (2003) Quetiapine adjunctive therapy for acute mania associated with bipolar disorder (SIAM) Paper presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CAGoogle Scholar
  85. Nasrallah HA, Hopkins T, Pixley SK (2010) Differential effects of antipsychotic and antidepressant drugs on neurogenic regions in rats. Brain Res 1354:23–29PubMedGoogle Scholar
  86. Newton SS, Duman RS (2007) Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 21(9):715–725PubMedGoogle Scholar
  87. Nikolaus S, Antke C, Muller HW (2009) In vivo imaging of synaptic function in the central nervous system: II Mental and affective disorders. Behav Brain Res 204(1):32–66PubMedGoogle Scholar
  88. O'Brien WT, Klein PS (2007) Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol Psychiatry 61(2):139–141PubMedGoogle Scholar
  89. Pearlson GD, Wong DF, Tune LE, Ross CA, Chase GA, Links JM et al (1995) In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 52(6):471–477PubMedGoogle Scholar
  90. Pereira M, Martynhak BJ, Baretta IP, Correia D, Siba IP, Andreatini R (2011) Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci Lett 500(2):95–98PubMedGoogle Scholar
  91. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE Jr (2006) Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 67(4):509–516PubMedGoogle Scholar
  92. Pinsonneault JK, Han DD, Burdick KE, Kataki M, Bertolino A, Malhotra AK et al (2011) Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology 36(8):1644–1655PubMedGoogle Scholar
  93. Popovic D, Reinares M, Amann B, Salamero M, Vieta E (2010) Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (Berl) 213(4):657–667Google Scholar
  94. Potkin SG, Keck PE Jr, Segal S, Ice K, English P (2005) Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 25(4):301–310PubMedGoogle Scholar
  95. Prieto E, Mico JA, Meana JJ, Majadas S (2010) Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder. Actas Esp Psiquiatr 38(1):22–32PubMedGoogle Scholar
  96. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V (2010) Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 68(2):156–162PubMedGoogle Scholar
  97. Roh MS, Seo MS, Kim Y, Kim SH, Jeon WJ, Ahn YM et al (2007) Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex. Exp Mol Med 39(3):353–360PubMedGoogle Scholar
  98. Rybakowski J (2005) Maintenance treatment of bipolar disorders. Neuro Endocrinol Lett 26(Suppl 1):49–65PubMedGoogle Scholar
  99. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL (2002) Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 159(7):1146–1154PubMedGoogle Scholar
  100. Sachs G, Chengappa KN, Suppes T, Mullen JA, Brecher M, Devine NA et al (2004) Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 6(3):213–223PubMedGoogle Scholar
  101. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W et al (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20(4):536–546PubMedGoogle Scholar
  102. Samuels BA, Hen R (2011) Neurogenesis and affective disorders. Eur J Neurosci 33(6):1152–1159PubMedGoogle Scholar
  103. Scheffer RE, Tripathi A, Kirkpatrick FG, Schultz T (2011) Guidelines for treatment-resistant mania in children with bipolar disorder. J Psychiatr Pract 17(3):186–193PubMedGoogle Scholar
  104. Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N et al (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 43(10):977–83Google Scholar
  105. Smith LA, Cornelius V, Warnock A, Bell A, Young AH (2007) Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 9(4):394–412PubMedGoogle Scholar
  106. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 15(1):75–84PubMedGoogle Scholar
  107. Suppes T, Brown E, Schuh LM, Baker RW, Tohen M (2005a) Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. J Affect Disord 89(1–3):69–77PubMedGoogle Scholar
  108. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR et al (2005b) The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 66(7):870–886PubMedGoogle Scholar
  109. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B (2009) Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 166(4):476–488PubMedGoogle Scholar
  110. Surja AA, Tamas RL, El-Mallakh RS (2006) Antipsychotic medications in the treatment of bipolar disorder. Curr Drug Targets 7(9):1217–1224PubMedGoogle Scholar
  111. Sutton LP, Rushlow WJ (2011) Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268. J Neurochem 117(6):973–983PubMedGoogle Scholar
  112. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A et al (2006) Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26(6):600–609PubMedGoogle Scholar
  113. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD et al (2008) Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 28(1):13–20PubMedGoogle Scholar
  114. Tohen M, Vieta E (2009) Antipsychotic agents in the treatment of bipolar mania. Bipolar Disord 11(Suppl 2):45–54PubMedGoogle Scholar
  115. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG et al (1999) Olanzapine versus placebo in the treatment of acute mania Olanzapine HGEH Study Group. Am J Psychiatry 156(5):702–709PubMedGoogle Scholar
  116. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG et al (2000) Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study The Olanzipine HGGW Study Group. Arch Gen Psychiatry 57(9):841–849PubMedGoogle Scholar
  117. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL et al (2002) Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 59(1):62–69PubMedGoogle Scholar
  118. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C et al (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60(11):1079–1088PubMedGoogle Scholar
  119. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM et al (2005) Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 162(7):1281–1290PubMedGoogle Scholar
  120. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R et al (2006) Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 163(2):247–256PubMedGoogle Scholar
  121. Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH et al (2006) Implementation of the texas medication algorithm project patient and family education program. J Clin Psychiatry 67(9):1362–1372PubMedGoogle Scholar
  122. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA (2007) Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 68(1):111–119PubMedGoogle Scholar
  123. Vestergaard P (1992) Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacology 7(4):249–259PubMedGoogle Scholar
  124. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M (2008a) Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 109(3):251–263PubMedGoogle Scholar
  125. Vieta E, T’Joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R et al (2008b) Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 165(10):1316–1325PubMedGoogle Scholar
  126. Vieta E, Nuamah IF, Lim P, Yuen EC, Palumbo JM, Hough DW et al (2010) A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 12(3):230–243PubMedGoogle Scholar
  127. Vieta E, Gunther O, Locklear J, Ekman M, Miltenburger C, Chatterton ML et al (2011) Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 14(8):1029–1049PubMedGoogle Scholar
  128. Wagstaff AJ, Easton J, Scott LJ (2005) Intramuscular olanzapine: a review of its use in the management of acute agitation. CNS Drugs 19(2):147–164PubMedGoogle Scholar
  129. Walburn J, Gray R, Gournay K, Quraishi S, David AS (2001) Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 179:300–307PubMedGoogle Scholar
  130. Weisler R, Dunn J, English P (2003) Ziprasidone in adjunctive treatment of acute bipolar mania: a randomized, placebo-controlled trial. Paper presented at the 16th congress of the European College of Neuro-psychopharmacology, Prague, Czech RepublicGoogle Scholar
  131. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B (2010) Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 72(11):1452–1464Google Scholar
  132. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A (2003) Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 182:141–147PubMedGoogle Scholar
  133. Yildiz A, Guleryuz S, Ankerst DP, Ongur D, Renshaw PF (2008) Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Arch Gen Psychiatry 65(3):255–263PubMedGoogle Scholar
  134. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011) Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 36(2):375–389PubMedGoogle Scholar
  135. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47–59PubMedGoogle Scholar
  136. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 276(34):31674–31683PubMedGoogle Scholar
  137. Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G et al (2010) Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 124(1–2):164–169PubMedGoogle Scholar
  138. Zarate CA, Manji HK (2009) Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs 23(7):569–582PubMedGoogle Scholar
  139. Zarate CA Jr, Singh JB, Carlson PJ, Quiroz J, Jolkovsky L, Luckenbaugh DA et al (2007) Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord 9(6):561–570PubMedGoogle Scholar
  140. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G et al (2005) The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25(18):4493–4502PubMedGoogle Scholar
  141. Zupancic ML (2011) Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature. Ann Clin Psychiatry 23(2):141–149PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Janssen Pharmaceutical Research and Development, L.L.C.TitusvilleUSA

Personalised recommendations